NYSE:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis → AI Bubble Now at Critical Mass (From Porter & Company) (Ad) Free AIM Stock Alerts $0.47 +0.03 (+6.28%) (As of 01:49 PM ET) Add Compare Share Share Today's Range$0.45▼$0.5050-Day Range$0.33▼$0.4552-Week Range$0.32▼$0.75Volume305,620 shsAverage Volume175,526 shsMarket Capitalization$22.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get AIM ImmunoTech alerts: Email Address Ad Porter & CompanyAI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.Simply click here now to read The Big AI Die-Up. About AIM ImmunoTech Stock (NYSE:AIM)AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Read More AIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIM Stock News HeadlinesMarch 23, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) Director Purchases $15,000.18 in StockMarch 19, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 37,879 SharesMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 28, 2024 | globenewswire.comAIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 26, 2024 | globenewswire.comAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastMarch 25, 2024 | globenewswire.comAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchMarch 25, 2024 | americanbankingnews.comInsider Buying: AIM ImmunoTech Inc. (NYSE:AIM) Director Buys $15,000.18 in StockMarch 22, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 20, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 19, 2024 | americanbankingnews.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Purchases 37,879 Shares of StockMarch 19, 2024 | americanbankingnews.comAIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels Buys 75,758 SharesMarch 19, 2024 | americanbankingnews.comAIM ImmunoTech Inc. (NYSE:AIM) Director Stewart Appelrouth Buys 90,910 Shares of StockMarch 18, 2024 | americanbankingnews.comFinancial Comparison: AIM ImmunoTech (NYSE:AIM) versus Eloxx Pharmaceuticals (NASDAQ:ELOX)March 15, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityMarch 9, 2024 | investing.comAIM ImmunoTech launches CEO Corner for direct stakeholder engagementMarch 7, 2024 | globenewswire.comAIM ImmunoTech Announces Launch of CEO Corner PlatformFebruary 29, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateFebruary 29, 2024 | globenewswire.comAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline DevelopmentsFebruary 15, 2024 | msn.comAIM ImmunoTech commences dosing in pancreatic cancer therapy trialFebruary 14, 2024 | finance.yahoo.comAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerFebruary 14, 2024 | globenewswire.comAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic CancerFebruary 10, 2024 | msn.comAIM ImmunoTech Touts Ampligen’s Post-COVID Study SuccessFebruary 9, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID ConditionsFebruary 8, 2024 | msn.comAIM stock dips amid mixed results for post-COVID fatigue therapyFebruary 5, 2024 | benzinga.comAIM ImmunoTech Stock (AMEX:AIM) Dividends: History, Yield and DatesSee More Headlines Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2023Today3/28/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees22Year Founded1990Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,440,000.00 Net Margins-10,764.25% Pretax Margin-10,764.25% Return on Equity-67.33% Return on Assets-59.60% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$140,000.00 Price / Sales154.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book0.56Miscellaneous Outstanding Shares48,840,000Free Float48,832,000Market Cap$21.64 million OptionableNot Optionable Beta-0.13 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Thomas K. Equels Esq. (Age 71)J.D., M.S., Executive Vice Chairman, CEO & President Comp: $1.24MMr. Robert Dickey IV (Age 68)M.B.A., Chief Financial Officer Comp: $60.98kMr. Peter W. Rodino III (Age 73)Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary Comp: $630kAnn Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations CoordinatorDr. Carol A. Smith (Age 73)Chief Manufacturing Officer & Deputy Chief Scientific Officer Comp: $170.77kDr. Christopher McAleer Ph.D.Scientific OfficerDr. Ralph Christopher Cavalli Ph.D. (Age 66)Vice President of QC & Manufacturing Comp: $234.79kJodie PelzDirector of FinanceMore ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSPharmaCyte BiotechNASDAQ:PMCBZIVO BioscienceNASDAQ:ZIVOSenti BiosciencesNASDAQ:SNTIAptose BiosciencesNASDAQ:APTOView All CompetitorsInsidersNancy BryanBought 38,462 shares on 3/21/2024Total: $15,000.18 ($0.39/share)Thomas K EquelsBought 75,758 shares on 3/15/2024Total: $25,000.14 ($0.33/share)Stewart AppelrouthBought 90,910 shares on 3/15/2024Total: $30,000.30 ($0.33/share)Peter W Rodino IIIBought 37,879 shares on 3/15/2024Total: $12,500.07 ($0.33/share)Thomas K EquelsBought 33,861 shares on 11/27/2023Total: $14,898.84 ($0.44/share)View All Insider Transactions AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed in 2024? AIM ImmunoTech's stock was trading at $0.4399 at the beginning of the year. Since then, AIM stock has increased by 6.9% and is now trading at $0.4701. View the best growth stocks for 2024 here. When is AIM ImmunoTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our AIM earnings forecast. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) announced its earnings results on Wednesday, November, 15th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.05. The firm earned $0.05 million during the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 67.33% and a negative net margin of 10,764.25%. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX). How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AIM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.